Background Chronic hepatitis B virus (HBV) infection can lead to fatal complications and death. Only a relatively small proportion of patients actually receive medication, and the majority requires long-term antiviral therapy that can result in the emergence of resistant strains of HBV. The study aimed to estimate the future burden of chronic hepatitis B in Spain over the next 20 years, the impact of current lamivudine treatment and the emergence of drug-resistant HBV.
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Methods We constructed a hypothetical cohort of people with active chronic HBV infection in Spain in 2005, and 'followed' the cohort for 20 years. The cohort was stratified with respect to factors that affect prognosis (i.e. hepatitis B e-antigen and histology-defined status). To estimate the burden, Markov mathematical simulation was performed based on three scenarios: natural history, treatment with antiviral drug (lamivudine) and treatment with a hypothetical drug with identical profiles to lamivudine but to which there is no resistance.
Results
We estimated that in 2005 there were around 111 000 individuals suffering from active chronic HBV infection. If the cohort is not treated, by the year 2025 there will be about 60 000 events of morbidity and 40 000 cases of liver-related deaths, with 1.84 billion euros expected to be consumed in providing care for the cohort. Treating 35% of the cohort with lamivudine will reduce the morbidity and mortality by 19 and 15%, respectively; whereas the hypothetical drug will reduce the morbidity and mortality by 27 and 24%. The cumulative cost savings resulting from the use of lamivudine and the hypothetical drug, respectively, are 160 and 300 million euros. Antiviral resistance accounts for a reduction of about one-third in the potential benefit of treatment, and almost a half of the potential cost saving.
Conclusion Chronic hepatitis B will pose a great burden in the future if the individuals with active disease are left untreated. Effective antiviral therapy and treatment coverage have substantial impact in reducing the future burden; however, antiviral resistance decreases treatment benefit considerably. Eur J Gastroenterol Hepatol 20:320-326 c 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Hepatitis B is considered to be of low priority in European countries' public health agenda [1] . This is probably owing to the asymptomatic course of the disease, and the relatively low prevalence as a result of successful vaccination programs and other universal preventive measures such as systematic screening of blood transfusion [2] [3] [4] . This perception, however, is changing owing to the awareness of the chronic consequences of hepatitis B virus (HBV) infection in terms of fatal complications and death [4] [5] [6] , and an increase in the number of acute cases resulting from immigration from countries where infection is high [7, 8] .
Although HBV vaccination coverage is generally high in developed countries [9, 10] , which clearly contributes to the decrease in new cases of HBV infection [3, 4] , vaccination per se does not have any impact on the prognosis of patients with existing chronic HBV infection. The only measure to reduce morbidity and mortality in patients with chronic infection is by the application of medication. One recent study in the Netherlands, however, reported that only a low proportion (39%) of chronic hepatitis B (CHB) patients eligible for therapy according to existing guidelines, received medication [11] .
Lamivudine was the first oral-route drug introduced, and is widely used for the treatment of CHB patients. The majority of patients requires long-term antiviral therapy, especially those with negative hepatitis B e-antigen (HBeAg), which often results in the emergence of HBV strains that are resistant to the drug [12, 13] .
Public health planning would benefit from mathematical models that estimate the future burden of chronic HBV infection together with the impact of treatment and resistance. The aim of this study was to estimate the future disease burden in terms of morbidity, mortality and cost related to chronic HBV infection in Spain over the next 20 years. We also aimed to estimate the potential impact of treatment with lamivudine and the emergence of HBV drug resistance on the future disease burden.
Methods

Markov model
We used Markov mathematical simulations to model prognosis by following, over a period of time, a representative cohort of CHB patients of different age groups. The Markov model was built using TreeAge Pro 2006 computer program (TreeAge Software Inc., Massachusetts, USA). The model describes disease progression and determines the long-term morbidity, mortality and lifetime costs of the cohort during the follow-up period. The model uses probabilities of progression from chronic hepatitis to cirrhosis, decompensated liver disease and, finally, death. Data entered into the model were derived from published studies (Table 1) [10, 14] .
The term morbidity was defined as events related to decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Hepatic death was that resulting from liver failure, or other liver-related complications. Other common causes of death not related to liver disease were included in the model, with rates obtained from the Spanish National Institute of Statistics [15] .
Cohort definition
The hypothetical cohort of patients with CHB was built using age-stratified prevalence of hepatitis B serum antigen (HBsAg) in the Spanish population [7] . We projected this prevalence to the 40 million individuals comprising the Spanish population in 2005 (data obtained from the National Institute of Statistics) [15] . HBsAg prevalence was stratified into two groups of HBeAg, that is, positive and negative according to the prevalence of HBeAg in earlier studies performed in Spain [16] .
We assumed that 63% of the HBeAg-positive patients and 16% of the HBeAg-negative patients had HBV DNA levels higher than 10 5 copies/ml and elevated transaminase (ALT) levels and, as such, had active liver disease [16] . This differentiation is important as progression of the disease follows different courses in these two groups of patients. Patients with elevated ALT levels and high HBV DNA levels have progressive liver disease and are candidates for HBV therapy, whereas those with normal ALT and low or undetectable HBV DNA levels usually are inactive carriers and, as such, these patients are at low risk of disease progression. In addition, using mathematical estimations based on previously published studies, we further stratified the patients according to their degree of liver damage into two categories: those with chronic hepatitis and those with cirrhosis [16, 17] .
Scenario analyses
Three different scenarios with different progression assumptions were analyzed in the study. In the first scenario, the natural history of CHB was simulated in which patients received all medical care excluding the antiviral medication to treat the infection. In the second scenario, patients received antiviral treatment (lamivudine monotherapy), and progressed to various treatmentrelated situations (e.g. virologic response, nonresponse, relapse and resistance). We estimated the impact of treatment by subtracting the burden in scenario 1 from that in scenario 2. To estimate the potential burden of lamivudine resistance, we built a third scenario in which patients were treated with a hypothetical drug with identical efficacy profile as lamivudine, but without antiviral resistance.
Scenario 1: natural history
In this scenario, CHB patients progressed according to the disease's natural history and followed certain annual rates of progression. These data were derived from a systematic literature review (Table 1) [14] , and transformed into annual probabilities using a standard formula [18] . The probabilities of proceeding to liver transplantation in decompensated cirrhosis and liver cancer were adjusted for country-specific conditions using a modified method of Stein et al. [19] . The adjustment takes into account the prevalence rates of HBsAg positivity [7] and the transplantation rates per million population [20] in Spain. We applied similar annual rates of mortality after successful transplantation as in the United States, as reported in a Spanish study on liver transplantation [21] . Background mortality rate for non-liver-related deaths or deaths from other causes were applied based on agespecific mortality rates of the Spanish population [15]. In this scenario, we assumed that 35% of patients received long-term therapy with oral-route lamivudine as recommended in the clinical guidelines [22, 23] . We defined virologic response in HBeAg-positive patients as an e-antigen loss and anti-HBe seroconversion. In HBeAg-negative patients, therapy response was defined as undetectable HBV DNA levels by unamplified assays ( < 10 5 copies/ml). Therapy in HBeAg-positive patients was discontinued after 6 months of response; whereas in HBeAg-negative patients, the therapy was continued for an indefinite period because several studies have shown that the probability of achieving a sustained virologic response after therapy discontinuation is very low [6] . We assigned different rates of virologic response to resistant and to nonresistant patients receiving long-term therapy, according to what was reported in a systematic review (Table 2 ) [10, 14, 22] .
Following current clinical practice guidelines, we assigned patients to long-term therapy until they developed a subsequent virologic response in those who did not respond to initial therapy or who had experienced relapse after initial response. We assumed that the disease stops progressing in patients who achieved virologic response, and therefore, they have the same mortality rates as the general population, that is, they will live up to the life expectancy for their particular age. In cases of nonresponse and viral resistance, the disease follows the natural history of progression [14] . Rates of progression from compensated to decompensated cirrhosis, however, were assumed to be higher in patients presenting with lamivudine resistance, compared with those without resistance ( Table 2 ) [24] .
Scenario 3: hypothetical drug
In this scenario, the same proportion of patients (35%) received a hypothetical drug that has identical efficacy and cost as lamivudine, but a hypothetical 0% value of annual probability of developing resistance. The same patient management strategy in scenario 2 was also applied in this scenario.
Costs of treatment
All cost components (Table 3 ) [23] pertain to annual cost per person, which is incurred as long as the patient is in a state that requires that particular treatment, except for the cost that is only incurred in the first year of that relevant state (e.g. liver transplantation). We used the third-party payer's perspective to estimate the costs of CHB management. Therefore, we only considered direct health-care costs of treating the patients. We separated the annual cost of lamivudine from other costs to analyze the cost in natural history (i.e. no antiviral treatment) scenario. Costs for lamivudine and management of chronic hepatitis complications in Spain were taken from our earlier study, adjusted to 2005 values [25] . Costs were derived from the management of the disease states, and included all related elements such as physician visits, laboratory testing and ultrasound examination. In the model, a 3% discount rate was applied to all costs [26] .
Assumptions and sensitivity analysis
We used other assumptions besides those on disease progression with respect to treatment-related states. First, we did not include new infections into the cohort. This was because of the difficulty in estimating these values and because of the nature of the disease the inclusion of new cases would not have a major impact until late in the follow-up. Second, the model did not consider the possibility of different prognostic determinants, or the influence of cofactors that would result in accelerated progression of the disease. These factors include patient's age, histological status when resistance develops, coinfection by another hepatitis virus or human immunodeficiency virus and alcohol consumption. The inclusion of these determinants would increase the progression and costs of the disease. Third, we assumed that patients who developed lamivudine resistance did not receive salvage therapy with other antiviral drugs. It is difficult to calculate the exact proportion of patients who would receive therapy in the population. A study on referral of CHB patients reported that only 39% of those eligible for antiviral therapy actually received the care recommended. The remaining patients not receiving the treatment could be as a result of lack of awareness of the disease, low potential benefit or contraindications to the use of the drug. Therefore, in the treatment scenario we assumed baseline coverage of 35% and performed oneway sensitivity analysis by doubling the assumption to 70%. We then analyzed how this would affect morbidity, mortality and cost. In the sensitivity analysis, we also took into account the cost of generic lamivudine, which, in the case of Spain, was assumed to be about 30% cheaper than the proprietary drug. Table 5 (morbidity), Fig. 1 (mortality) and Fig. 2 (cost) . In 20 years, if the cohort is not treated, there will be around 60 000 morbidity events (Table 5) , and 40 000 individuals (36% of the cohort) will have died owing to liver-related complications (Fig. 1) .
Results
Cohort definition and natural history
It is estimated that the cumulative expenditure in caring for the cohort will increase over the years of follow-up. Thus, by the year 2025, the untreated cohort is expected to have consumed 1.84 billion euros (Fig. 2) , with the largest expenditure being related to the cost of liver transplantation.
Impact of treatment with lamivudine and potential burden related to drug resistance
Treating 35% of the cohort with lamivudine, will decrease the number of events to less than 50 000 (Table 5 ) and the mortality to 34 371 cases ( Fig. 1) , whereas the total expenditure will be 1.68 billion euros. Treating the same proportion of patients with the hypothetical drug will further decrease the morbidity events to around 45 000 and mortality to 30 823. The expenditure under this scenario is estimated to be 1.54 billion euros. In all three scenarios, the largest contributor to morbidity is hepatocellular carcinoma, followed by liver transplantation and decompensated cirrhosis. The largest expenditure is on liver transplantation, followed by the cost of CHB with the other contributors being relatively small.
Comparing the three scenarios, lamivudine will reduce the burden of morbidity by 11 381 cases (19%), whereas the hypothetical drug would cause a reduction of 16 122 cases (27%) from the total of 60 479 cases. Using the case reduction of the hypothetical drug, which has no resistance as comparison, almost one-third of the standard treatment potential benefit is lost because of antiviral resistance.
Lamivudine would prevent 5947 (15%) of CHB-related deaths that would otherwise occur in the natural history scenario, whereas treatment with the hypothetical drug would prevent 9495 deaths (24%). Thirty-seven percent of the drug's potential in preventing death is lost because of viral resistance.
In terms of cost, treatment with lamivudine could save 160 million euros in total cumulative expenditure, whereas 300 million euros could be saved by using the hypothetical drug. In other words, almost half of the costsaving potential of the antiviral treatment is lost because of resistance to the antiviral drug.
Model validation
We validated the model using data derived from a MEDLINE search of the literature using keywords hepatitis B and natural history and cohort. From 42 titles retrieved, only one article fulfilled the predetermined criteria: (i) the study to contain original data on liverrelated deaths; (ii) the patients to have chronic active hepatitis B virus infection; (iii) the number of patients to be Z 100; and (iv) the patients not having coinfections and other comorbidities. The cumulative 5-year survival probability of patients with untreated compensated cirrhosis (n = 161) reported by the study (86%) matched the result (85.7%) predicted by our model (results not shown) [27] .
Sensitivity analyses
Doubling the treatment coverage from 35 to 70% will decrease the morbidity in 20 years to 38 215 and 28 234 cases in lamivudine and hypothetical drug scenario, respectively; and the mortality to 28 425 and 21 327, respectively. The total expenditure will be 1.47 and 1.21 billion euros with lamivudine and hypothetical drug, respectively ( Table 6 ). The reductions on the disease burden are approximately twofold that in the 35% treatment cover. Taking into account the sought-after objective of a generic version of lamivudine becoming available did not alter the outcome significantly; merely a very small reduction in the total costs was observed (results not shown).
Discussion
Although the registered prevalence is relatively small, the actual number of CHB cases in Spain in 2005 was relatively large (around half a million). A quarter of these patients have active disease, which, if untreated, will progress into liver-related complications and put a considerable burden on health-care expenditure. Treating a modest proportion (35%) of the patients with lamivudine will reduce some of the liver-related mortality and morbidity, and the health-care-associated costs. Hepatitis B viral resistance, however, reduces by approximately one-third of the agent's potential efficacy in preventing complications of the disease. The extent of treatment coverage has a major effect on future projections; as shown in the sensitivity analysis, doubling the coverage will double the benefit of treatment by reducing the burden of CHB.
Our study has several strengths. We constructed the cohort in such a way that relevant aspects related to disease progression and response-to-treatment were incorporated, that is, age, HBeAg and histology status. We modified recently published models using transition estimates that were based on current evidence derived from an extensive literature review. We also validated the model using the longest follow-up study available to date, and that our predictions were very similar to the outcomes reported in the published study. We performed the analyses for each scenario as realistically as possible by simulating the cohort separately on the basis of age, HBeAg and histology status, as these factors would affect the prognosis. For the treatment scenario, the models simulated long-term treatment as recommended by the guidelines, rather than that of merely the first year of treatment.
CHB is a very heterogeneous disease entity. It is clear that even rigorously performed mathematical modeling cannot replace a systematic follow-up study as the full dynamic of the disease cannot be captured in a model [28, 29] . It is difficult, however, to calculate the burden of CHB and the potential consequences of antiviral resistance from a follow-up study because of the chronic nature of the disease. It needs to be stated that our outcomes analyses apply only to the Spanish situation.
Other limitations of our study are that we used simplifying assumptions such as not considering coinfection with other diseases that would accelerate the progression, not adding new cases to the cohort, estimating disease progression as being the same across age groups, and not considering salvage therapy, that is, switching to other drugs in case of resistance. Nevertheless, we believe that our results provide relatively valid public health estimates of the future burden of CHB and the impact of therapy.
We have estimated the future burden of CHB and have quantified the impact of therapy and antiviral resistance at the population level. Other studies in hepatitis B used mathematical modeling to compare cost-effectiveness of various antiviral drugs [14, 24] , and to predict future impact of vaccination programs in preventing HBV-related death [30] . The later study estimated that the global burden of HBV infection will increase in the future, and that most of the burden will be because of chronic complications of the disease. Other studies using Markov simulation to estimate disease burden at the population level were on chronic hepatitis C in Spain [31] and the United States [32] , which reported that the burden would increase in the future.
Conclusion
CHB will pose a great burden in the future if the individuals with active disease are left untreated. Our simulation showed that antiviral therapy and treatment coverage have substantial impact on the reduction of the future burden of CHB. Antiviral resistance, however, decreases the treatment benefit considerably. Therefore, there is a need to increase the effectiveness of treatment by devising strategies that can prevent resistance, increase the rate of sustained virologic response, improve case identification and the subsequent chain of referral so as to ensure that as many patients as possible receive the necessary treatment.
